References

Bouchelet I, Case B, Olivier A, Hamel E (2000). No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br. J. Pharmacol. 129: 501-508

Goadsby PJ, Lipton RB, Ferrari M (2002). Migraine – current understanding and treatment.  N. Engl. J. Med. 346: 257-270

Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). Selective serotonin 1F (5HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 358: 1230-1234

Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999). Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159: 813-818

Mitsikostas DD, del Rio MS, Moskowitz MA, Waeber C (1999). Both 5HT1B and 5HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur. J. Pharmacol. 369: 271-277

Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). Possible anti-migraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19: 851-858